BACKGROUND {#S5}
==========

Critically ill patients with coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), progress to hypoxemic and then mixed respiratory failure, secondary to acute respiratory distress syndrome (ARDS) ([@R1], [@R2]). Approximately 79--88% of patients admitted to the intensive care unit (ICU) with COVID-19 require intubation and mechanical ventilation, with a mortality of 24--53% ([@R3]--[@R6]). ARDS in COVID-19 is characterized by ventilation failure, in part attributable to distally located mucopurulent secretions.

Dornase alfa (Pulmozyme®) is recombinant human DNase 1 and a safe mucolytic that is administered in nebulized form. It is FDA-approved in combination with standard therapies for patients with cystic fibrosis to improve sputum clearance and pulmonary function ([@R7]). It is also used off-label as a mucolytic in other diseases, including ARDS ([@R8], [@R9]). A mechanism by which dornase alfa might improve ventilation is by reducing the DNA-mediated viscosity of neutrophil-rich secretions ([@R10]). There are multiple sources for the DNA in mucoid sputum, one of which is neutrophil extracellular traps (NETs). Recently, we collaboratively reported that in the discarded serum of patients with COVID-19, the levels of NETs were increased and were correlated with lactate dehydrogenase (LDH), D-dimer, and C-reactive protein (CRP) levels ([@R11]). Targeting NETs reduces mortality in animal models of ARDS ([@R12]). Despite recognition that mucolytic treatment may be beneficial for patients with COVID-19, administration of nebulized medications, such as dornase alfa, have been limited due to risk of viral aerosolization. If risk of viral aerosolization can be avoided, dornase alfa may benefit patients with severe COVID-19. by acting as a mucolytic and by reducing NET levels in the lungs, thereby improving oxygenation and ventilation. We report the clinical course, safety, and outcomes after nebulized in-line endotracheal dornase alfa treatment for five intubated and mechanically ventilated patients with PCR-confirmed COVID-19.

METHODS {#S6}
=======

The Northwell Health institutional review board that focuses on COVID-19 research approved this case series as minimal-risk research using de-identified data from routine clinical practice. Data were collected from the enterprise health record (Sunrise Clinical Manager; Allscripts) reporting database, and included patient demographics, comorbidities, inpatient medications, laboratory studies, treatment, and outcomes. We further obtained longitudinal values of FiO~2~ and of the arterial partial pressure of carbon dioxide (PaCO~2~) as measures of respiratory function during treatment. FiO~2~ values of the circuit were reported for those patients who required veno-venous extracorporeal membrane oxygenation (VV-ECMO). Ferritin, CRP, LDH, and D-dimer were obtained as measures of systemic disease and inflammation. Not all patients had laboratory investigations on the same days in relation to the nDA+A treatment. In the following case synopses, each measurement is therefore followed by the day in relation to the first day of treatment with nDA+A (*e.g.* d 2 for the second day of treatment with nDA+A or d −1 for the day before nDA+A treatment was initiated).

RESULTS {#S7}
=======

Five patients treated with dornase alfa between March 31, 2020 and April 24, 2020 were identified. These patients had met the Berlin criteria for ARDS and were treated with ventilator strategies guided by the ARDSNet protocol at North Shore University Hospital within Northwell Health ([@R13]). They had been treated with dornase alfa because they required high levels of fraction of inspired oxygen (FiO~2~) and had elevated ventilation demands. All patients received the same treatment doses: nebulized dornase alfa (2.5 mg) co-administered twice daily with the short-acting β~2~-agonist albuterol (2.5 mg, hereafter abbreviated as nDA+A) to improve delivery to the alveoli. Of note, β~2~-adrenoreceptor agonism may also inhibit NET formation by direct action on neutrophils ([@R14]). The treatment was administered with an Aerogen® Solo in-line nebulizer to avoid open aerosol generation, which would place staff at risk of exposure to SARS-CoV-2.

The patient characteristics are summarized in [Table 1](#T1){ref-type="table"}. Patients were treated with nDA+A between 3 to 25 days. The most common characteristics of the patients included obesity (BMI≥30) and four of the patients had hypertension. Four patients received methylprednisolone dosed at 1--2mg/kg/day. All patients were treated with full dose or prophylactic dose anticoagulation for thrombosis. All other medications that were administered during the course of hospitalization are summarized in [Table S1](#SD1){ref-type="supplementary-material"}. The clinical course of the five patients treated with nDA+A is summarized in [Figure 1](#F1){ref-type="fig"}. [Figure 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} display the longitudinal, ventilatory, and inflammatory markers for each patient.

Patient 1 is a 56-year-old Hispanic woman who presented in respiratory distress. Her respiratory status deteriorated over 48 hours, requiring intubation and transfer to the ICU. She was treated with nDA+A for six days, starting from day 9 of intubation. The FiO~2~ requirement decreased from 70% (d −1) to 30% (d 6), PaCO~2~ from 58 (d −1) to 37 mmHg (d 7), ferritin from 1,803 (d −1) to 472 ng/mL (d 6), and D-dimer from 1,619 (d −1) to 563 ng/mL (d 6). Minimal changes were noted in CRP and LDH. The patient underwent a tracheostomy after 23 days of endotracheal intubation and remains on an FiO~2~ of 30% while pending return of mental status.

Patient 2 is a 34-year-old white man who presented to the hospital in diabetic ketoacidosis without prior history of diabetes mellitus. He was intubated on admission and initiated on VV-ECMO. He received nDA+A for three days and was de-cannulated after 12 days. The FiO~2~ requirement decreased from 100% (d 0) to 80% (d 3), CRP from 14.14 (d 0) to 2.41 mg/dL (d 3), ferritin from 12,281 (d 0) to 5,453 ng/mL (d 3), and D-dimer from 5,210 (d 0) to 2,099 ng/mL (d 3). Minimal changes were noted in PaCO~2~ and LDH. The patient remains intubated.

Patient 3 is a 65-year-old Asian man who was admitted directly to the ICU for respiratory distress and intubated three days later. Twelve days after intubation, he was started on nine days of nDA+A treatment. The FiO~2~ requirement decreased from 50% (d −1) to 40% (d 7), PaCO~2~ from 55 (d 0) to 43 mmHg (d 6), and CRP from 22.07 (d 0) to 26.48 mg/dL (d 6). Minimal changes were noted in ferritin, LDH, and D-dimer. He was extubated one day after the completion of the nDA+A course. Six days later, he was re-intubated for an additional four days due to mental status changes and failure to protect his airway. The patient remains extubated in ICU care.

Patient 4 is a 31-year-old Hispanic man who was intubated and transferred to the ICU from the Internal Medicine service two days after presenting with respiratory distress. Nine days after intubation, he was initiated on VV-ECMO. Five days after cannulation, he was started on the nDA+A treatment. After nine days, he was de-cannulated and remained intubated for ten days while continuing the nDA+A treatment. He was then extubated and discharged to the floor. The FiO~2~ requirement decreased from 90% (d −1) to 21% (d 7) and LDH from 1,054 (d −1) to 451 U/L (d 7). Ferritin initially decreased from 1,669 (d −1) to 387 ng/mL (d 7). On day 15 of treatment, he developed methicillin-resistant *Staphylococcus aureus* (MRSA) pneumonia and bacteremia. Ferritin thus increased to 1,619 ng/mL (d 13) prior to decreasing to 555 ng/mL (d 19) with antibiotic treatment. Minimal changes were noted in PaCO~2~, CRP, and D-dimer.

Patient 5 is a 34-year-old black woman who was intubated at an outside hospital, then transferred to the North Shore University Hospital ICU. Two days later, she was cannulated for VV-ECMO. She required VV-ECMO for 13 days and was intubated for a total of 29 days. She was treated with nDA+A for 25 days starting three days following intubation and cannulation. While on VV-ECMO for the first five days, CytoSorb therapy was applied. She was de-cannulated after 23 days, extubated after 4 days, and discharged to the floor. The FiO~2~ requirement fell from 80% (d −1) to 40% (d 7), ferritin from 1,244 (d −1) to 535 ng/mL (d 7), and LDH from 844 (d −1) to 693 U/L (d 7). Minimal changes were noted in PaCO~2~, CRP, and D-dimer.

DISCUSSION {#S8}
==========

At the doses utilized, no nDA+A treatment-associated toxicities were identified. FiO~2~ requirements decreased for all five patients seven days after nDA+A treatment was initiated. All patients remain alive at the time of submission of this report, with two patients discharged from the ICU. We recognize that these FiO~2~ changes may be independent of the nDA+A treatment. Clinical trials are therefore required to test the dose range, safety, and efficacy of dornase alfa in patients with COVID-19 in this setting and possibly earlier in the disease course. Endpoints should include measurements of the effect on respiratory function as well as on systemic inflammation, coagulopathy, secondary infections, and the presence of NETs in plasma. Two such trials were recently registered ([NCT04359654](https://clinicaltrials.gov/ct2/show/NCT04359654) and [NCT04355364](https://clinicaltrials.gov/ct2/show/NCT04355364)).

It is not clear whether nebulized dornase alfa will have any effect on blood NET levels or systemic inflammation in COVID-19, but a reduction in systemic inflammatory markers has been reported after use of dornase alfa in patients with cystic fibrosis ([@R7]). We did note a reduction in CRP in two patients (patients 2 and 3) and a reduction in D-dimer in two patients (patients 1 and 2) during nDA+A treatment. LDH was reduced for the patients on VV-ECMO during nDA+A treatment, and ferritin was reduced in four out of five patients. Due to the small sample size and the common occurrence of secondary infections in ventilated patients with COVID-19, we are unable to comment on any potential relationship between nDA+A administration and the risk of secondary infections.

CONCLUSIONS {#S9}
===========

Nebulized dornase alfa in combination with albuterol may be a safe treatment option for mechanically ventilated patients with ARDS secondary to COVID-19, including for those on VV-ECMO---a patient population with an urgent, unmet need for effective therapies.
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![Overview of the clinical course of five patients treated with nebulized dornase alfa + albuterol (nDA+A).](nihpp-2020.05.13.20087734-f0001){#F1}

![Patient-level data of respiratory function during treatment with nebulized dornase alfa + albuterol (nDA+A).\
Values were extracted from the medical records the day before and up to the seven days after the initiation of treatment. Values are graphed in black for patients after they ceased nDA+A treatment. Dashed lines indicate patients on VV-ECMO. Not all markers were measured daily for every patient. FiO~2~: fraction of inspired oxygen; PaCO~2~: partial pressure of carbon dioxide.](nihpp-2020.05.13.20087734-f0002){#F2}

![Patient-level data of systemic disease during treatment with nebulized dornase alfa + albuterol (nDA+A).\
Values were extracted from the medical records the day before and up to the seven days after the initiation of treatment. Values are graphed in black for patients after they ceased nDA+A treatment. Dashed lines indicate patients on VV-ECMO. Not all markers were measured daily for every patient. CRP: C-reactive protein; LDH: lactate dehydrogenase.](nihpp-2020.05.13.20087734-f0003){#F3}

###### 

Patient data from five patients with COVID-19 who received dornase alfa with albuterol March--April, 2020.

  Patient                                                                                      1                            2            3           4                          5
  -------------------------------------------------------------------------------------------- ---------------------------- ------------ ----------- -------------------------- --------------------------
  **Clinical Characteristics**                                                                                                                                                  
  Date of admission                                                                            29 March                     4 April      16 March    16 March                   26 March
  Age                                                                                          56                           34           65          31                         34
  Gender                                                                                       F                            M            M           M                          F
  Ethnicity                                                                                    Hispanic                     White        Asian       Hispanic                   Black
  BMI                                                                                          38                           41           32          30                         38
  Date of ICU admission                                                                        31 March                     4 April      16 March    18 March                   26 March
  Comorbidities                                                                                                                                                                 
   Hypertension                                                                                Yes                          Yes          Yes         Yes                        
   Diabetes mellitus, type 2                                                                   Yes                                                                              
   Asthma                                                                                      Yes                                       Yes                                    Yes
   Hyperlipidemia                                                                                                           Yes                                                 
   Migraine                                                                                                                                                                     Yes
   Chronic gastritis                                                                                                                                                            Yes
  **ECMO**                                                                                                                                                                      
  Date of ECMO initiation                                                                      \-                           4 April      \-          27 March                   28 March
  Date of ECMO cessation                                                                       \-                           16 April     \-          10 April                   20 April
  **Dornase alfa (DA) + albuterol (A) parameters**                                                                                                                              
  Administration (DA: 2.5 mg, A: 2.5 mg, both twice daily using the Aerogen® Solo nebulizer)                                                                                    
  Date of DA + A initiation                                                                    9 April                      4 April      31 March    1 April                    31 March
  Date of DA + A cessation                                                                     14 April                     6 April      8 April     19 April                   24 April
  Toxicities                                                                                   None                         None         None        None                       None
  **Other COVID-19 treatment**                                                                                                                                                  
   Methylprednisolone                                                                          Yes                          Yes                      Yes                        Yes
   Anakinra                                                                                                                 Yes                      Yes                        
   CytoSorb                                                                                                                                                                     Yes
  **Anticoagulants** [\*](#TFN1){ref-type="table-fn"}                                                                                                                           
   Enoxaparin                                                                                  40 mg BID                    120 mg BID   40 mg BID   100 mg BID                 120 mg BID
   Argatroban                                                                                                               Yes                      Yes                        Yes
   Heparin gtt                                                                                                                           Yes                                    Yes
  **Venous thromboembolism**                                                                   None                         None         None        Right SDVT Right CVT       None
  **Current State**                                                                            Recovery post tracheostomy   Intubated    Recovery    ICU discharge (23 April)   ICU discharge (28 April)

Patients were not on simultaneous anticoagulation therapies. BMI: body mass index; ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation; BID: bis in die (twice a day); gtt: guttae (intravenous drip); SDVT: soleal deep vein thrombosis; CVT: cephalic vein thrombosis.
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